New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

PAB Insider Trading

Insider Ownership Percentage: 30.76%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Patrys Insider Trading History Chart

This chart shows the insider buying and selling history at Patrys by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Patrys Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PAB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Patrys Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2023James CampbellInsiderExpiry399,415A$0.01A$3,994.15
12/6/2021John ReadInsiderIssued50,432A$0.04A$1,765.12
11/18/2021James CampbellInsiderIssued25,000,000A$0.04A$1,000,000.00
9/2/2021James CampbellInsiderBuy9,000,000A$0.01A$63,000.00
See Full Table
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for Patrys (ASX:PAB)

5.78% of Patrys stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Patrys logo
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.
Read More on Patrys

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

250,000 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

8.82%

Beta

0.28

Who are the company insiders with the largest holdings of Patrys?

Patrys' top insider shareholders include:
  1. James Campbell (Insider)
Learn More about top insider investors at Patrys.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!